Compare Smith & Nephew plc (SNN) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.07. The key difference: Smith & Nephew plc pays a 2.85% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | VIG | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | — |
52-Week High | $38.53 | $246.61 |
52-Week Low | $27.80 | $210.70 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
VIG trades at $240.11, down 0.79% with bearish technical signals from moving averages. The ETF maintains its dividend growth strategy, with a scheduled $1.00 dividend payment in June 2026. Recent news highlights institutional accumulation and comparisons with peer dividend ETFs, emphasizing VIG's defensive tech exposure and lower yield relative to competitors like SCHD.
Outlook remains cautious near-term due to technical pressure, but long-term dividend growth appeal persists for income-focused investors. Risks include interest rate sensitivity and yield competition, while institutional buying signals underlying confidence in the strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
